Noticias de NTLA_US

Noticias del mercado

Últimas noticias sobre NTLA_US — 284 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NTLA_US ✕ 284 resultados
27/04/2026 NTLA_US — Investing News Network
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
27/04/2026 NTLA_US — Intellia Therapeutics
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04/2026 NTLA_US — Stock Titan
One CRISPR dose left 62% of HAE patients attack- and therapy-free
27/04/2026 NTLA_US — Intellia Therapeutics
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026 NTLA_US — Stock Titan
One-shot gene-editing treatment for swelling disorder heads to FDA
27/04/2026 NTLA_US — Sahm
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
27/04/2026 NTLA_US — Yahoo Finance
Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data
27/04/2026 NTLA_US — Investing.com
BofA raises Intellia Therapeutics stock price target on HAE data
27/04/2026 NTLA_US — Investing News Network
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
27/04/2026 NTLA_US — GlobeNewswire
Intellia Announces Proposed Public Offering of Common Stock
27/04/2026 NTLA_US — Stock Titan
Intellia (NTLA) hits Phase 3 HAE success and starts BLA for lonvo-z
27/04/2026 NTLA_US — Sahm ES ← EN
Intellia anuncia propuesta de oferta pública de acciones ordinarias

Intellia Announces Proposed Public Offering of Common Stock

27/04/2026 NTLA_US — Investing.com
TD Cowen reiterates Intellia Therapeutics stock rating on phase 3 data
26/04/2026 NTLA_US — Stocktwits
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy

Lonvo-z es una terapia única que desactiva el gen KLKB1, que desencadena ataques de hinchazón en el angioedema hereditario.

25/04/2026 NTLA_US — MSN
NTLA stock rises 20% in 3 months: Here's what you should know
25/04/2026 NTLA_US — MarketBeat ES ← EN
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recibió una calificación de consenso de "mantener" por parte de las casas de bolsa

Las acciones de Intellia Therapeutics, Inc. (NASDAQ:NTLA - Obtenga un informe gratuito) han obtenido una calificación promedio de "Mantener" de las veinte casas de bolsa que cubren las acciones, informa MarketBeat.com. Dos analistas de investigación de acciones calificaron la acción con una calificación de venta, ocho le asignaron una calificación de retención, n

25/04/2026 NTLA_US — Sahm ES ← EN
Intellia prepara la primera fase 3 de la prueba CRISPR in vivo para la tesis de AEH

Intellia Readies First Phase 3 In Vivo CRISPR Test For HAE Thesis

25/04/2026 NTLA_US — Moomoo
Intellia Therapeutics Insiders Placed Bullish Bets Worth US$2.41m
25/04/2026 NTLA_US — MSN ES ← EN
Intellia Therapeutics mejorada por Citizens JMP en la oportunidad HAE, las acciones suben un 6%

Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6%

24/04/2026 NTLA_US — GuruFocus
Intellia Therapeutics (NTLA) Set to Release Phase 3 Data for Her

Página 10 de 15

keyboard_arrow_up